Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

June 18th 2024

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Zanubrutinib rendering | Image credit: molekuul.be - stock.adobe.com
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Continuing Medical Education
View All
December 21st 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
December 21st 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

ASH 2022: Leukemia and Lymphoma
February 4th 2023

ASH 2022: Leukemia and Lymphoma

Mary Caffrey Laura Joszt, MA Hayden E. Klein
Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.
Child in hospital bed
February 3rd 2023

Racial and Ethnic Disparities Persist in B-Cell ALL Survival in Children, Young Adults

Rose McNulty
Despite overall improvements in survival outcomes in recent decades, disparities in survival outcomes persist among children and young adults with acute lymphocytic leukemia (ALL) across racial and ethnic groups.
Challenges with BTKis in CLL, MCL, and SLL
February 1st 2023

Challenges with BTKis in CLL, MCL, and SLL

A panel of experts discuss the provider, payer, and patient challenges that must be considered with BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma.
BTKi Landscape for CLL, MCL, and SLL
February 1st 2023

BTKi Landscape for CLL, MCL, and SLL

Callie Coombs, MD, discusses recent changes you have seen in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL) and provides an overview of the Bruton tyrosine kinase inhibitor landscape for CLL, MCL, and SLL.
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023

Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL

Mary Caffrey
New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023

PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant

Mary Caffrey
Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Examining Safety, Efficacy of Pirtobrutinib in CLL/SLL, MCL, and WM; Results Seen for Patients With Intolerance to Covalent BTK Inhibitors
January 27th 2023

Examining Safety, Efficacy of Pirtobrutinib in CLL/SLL, MCL, and WM; Results Seen for Patients With Intolerance to Covalent BTK Inhibitors

Mary Caffrey
In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.
Goals of Therapy for CLL, MCL, and SLL Patients
January 25th 2023

Goals of Therapy for CLL, MCL, and SLL Patients

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.
Prevalence, Diagnosis, and Management of CLL, MCL, and SLL
January 25th 2023

Prevalence, Diagnosis, and Management of CLL, MCL, and SLL

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.
Overview of CLL, MCL, and SLL
January 25th 2023

Overview of CLL, MCL, and SLL

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.
Researchers Form Novel Database of Leukemia Transcriptome Profiles
January 20th 2023

Researchers Form Novel Database of Leukemia Transcriptome Profiles

Rose McNulty
A recent study aggregated RNA sequencing data from more than 3000 samples to create a user-friendly database of transcription profiles in leukemia and related cell lines.
FDA Gives Zanubrutinib Approval for First-line, R/R CLL/SLL
January 19th 2023

FDA Gives Zanubrutinib Approval for First-line, R/R CLL/SLL

Mary Caffrey
The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Image of DNA
January 14th 2023

cfDNA May Help Risk-Stratify Patients With ALL

Jared Kaltwasser
The study authors said the method also has the advantages of having a quick turnaround and a relatively low cost.
Image of blood in test tubes and leukemic cells
January 10th 2023

Case Report Highlights Rare Case of CML Presenting With Morel Lavallée Lesion

Jared Kaltwasser
The case is believed to be just the second reported in the scientific literature.
Blood cells
January 7th 2023

Impact of Patient Factors on Developing AML After MDS or CML; Ponatinib in Highly Resistant CP-CML

Laura Joszt, MA
Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.
graphic of leukemia cell
December 29th 2022

Abstracts Highlight the Efficacy of BCL-2 Inhibitors in AML and CLL

Laura Joszt, MA
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
image of the box for lunsumio
December 23rd 2022

FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma

Laura Joszt, MA
The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.
Top 5 leukemia and lymphoma articles.
December 20th 2022

Top 5 Most-Viewed Content in Leukemia and Lymphoma for 2022

Matthew Gavidia
The top 5 most-read content in leukemia and lymphoma for 2022 addressed chimeric antigen receptor T-cell therapy, updates in recommended treatment, and President Joe Biden’s announcement on the return of the Cancer Moonshot.
medical symbol, stethoscope, pills on top of a print out of lab tests
December 16th 2022

ICYMI: Top Content From ASCO 2022

AJMC Staff
The top news out of the annual meeting of the American Society of Clinical Oncology (ASCO) highlighted findings in gliobastoma, HER2-low breast cancer, and Hodgkin lymphoma.
P13k inhibitor
December 12th 2022

PI3K Inhibitors Face Challenges in Hematologic Malignancies

Anita T. Shaffer
The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.
leukemia cell
December 2nd 2022

Review of BTK Inhibitors for Waldenström Macroglobulinemia Highlights Pros, Cons, and Future Directions

Rose McNulty
Bruton tyrosine kinase (BTK) inhibitors are currently the only FDA-approved agents indicated specifically for patients with Waldenström macroglobulinemia.
Joseph Alvarnas, MD.
November 23rd 2022

Dr Joseph Alvarnas Discusses Nationwide Implications of the California Cancer Care Equity Act, Opportunities for Federal Legislation

Matthew Gavidia
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on the influence that the California Cancer Care Equity Act is having on legislative efforts in other states, as well as future steps to promote accessible, affordable, and effective cancer care for patients nationwide.
chronic lymphocytic anemia
November 12th 2022

Strategies for Managing Autoimmune Complications in CLL

Rose McNulty
While chronic lymphocytic leukemia (CLL) typically progresses slowly, awareness of rare but potentially serious complications is crucial to improve outcomes.
graphic depicting targeted therapy
November 8th 2022

Data Suggest Next-Gen BTK Inhibitor Is More Favorable in Rare Form of NHBCL

Jaime Rosenberg
Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.
patient research
November 6th 2022

Could Combining Use of BTK Inhibition, CAR T-Cell Therapy Yield Better Outcomes in MCL?

Jaime Rosenberg
Recent research suggested the idea of combining chimeric antigen receptor (CAR) T-cell therapy and Bruton’s tyrosine kinase (BTK) inhibitors for certain patients with advanced mantle cell lymphoma (MCL).
BeiGene, Ontada Announce Strategic Alliance to Develop RWE, Improve Access to Oncology Therapies
October 22nd 2022

BeiGene, Ontada Announce Strategic Alliance to Develop RWE, Improve Access to Oncology Therapies

Advances in Cancer Care Demand Access for All, City of Hope Leaders Say
October 21st 2022

Advances in Cancer Care Demand Access for All, City of Hope Leaders Say

Mary Caffrey
Coverage from the Irvine, California, meeting of the Institute for Value-Based Medicine, chaired by Joseph Alvarnas, MD, vice president for government affairs at City of Hope and chief clinical advisor, AccessHope.
Topline Results of Phase 3 Trial Show Zanubrutinib Achieves Superior PFS Results Over Ibrutinib in CLL
October 17th 2022

Topline Results of Phase 3 Trial Show Zanubrutinib Achieves Superior PFS Results Over Ibrutinib in CLL

AJMC Staff
Results will be presented at an upcoming medical conference.
Chronic lymphocytic leukemia
October 14th 2022

Applications, Future Directions of BTK Inhibitors in Blood Cancers and Autoimmune Disorders

Rose McNulty
A recent review summarized the current landscape of Bruton tyrosine kinase (BTK) inhibitors in both hematological cancers and inflammatory disorders.
Image of the symbols of male and female
October 10th 2022

Study Highlights Sex Differences in Lymphoma Incidence and Mortality

Rose McNulty
A Swedish population-based study adds to data suggesting men have a higher risk of lymphoma and likely higher mortality.
<12345678
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo